Pfizer Builds On AI/ML Pact With CytoReason With New Five-Year Deal
Deal Snapshot: The companies first partnered in January 2019, with a focus on more than 20 diseases. The renewed deal will support development of additional disease models using artificial intelligence and machine learning.
You may also be interested in...
CEO Fabrice Chouraqui spoke with Scrip about the company’s new $121m financing and its use of machine learning to target the whole cell instead of molecular targets in novel therapies.
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
Accenture released its Life Sciences Technology Vision 2022 report, including a survey of biopharma execs on trends like synthetic data and quantum computing.